Cover Image
市場調查報告書

心肌纖維症:開發中產品分析

Myocardial Fibrosis - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 350076
出版日期 內容資訊 英文 82 Pages
訂單完成後即時交付
價格
Back to Top
心肌纖維症:開發中產品分析 Myocardial Fibrosis - Pipeline Review, H1 2016
出版日期: 2016年06月08日 內容資訊: 英文 82 Pages
簡介

心肌纖維症是由於心臟纖維芽細胞不正常增生造成心臟瓣膜異常肥大的疾病。症狀有胸部疼痛,腹部的膨脹滿感,噁心,疲勞感等。

本報告提供全球心肌纖維症治療用的開發中產品的開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

心肌纖維症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

心肌纖維症:企業開發中的治療藥

心肌纖維症:大學/機關研究中的治療藥

心肌纖維症:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

心肌纖維症:企業開發中的產品

心肌纖維症:大學/機關研究中的產品

心肌纖維症治療藥的開發企業

  • AstraZeneca Plc
  • BioLineRx, Ltd.
  • Digna Biotech, S.L.
  • Evotec AG
  • Galectin Therapeutics, Inc.
  • GTx, Inc.
  • MandalMed, Inc.
  • miRagen Therapeutics, Inc.
  • ProMetic Life Sciences Inc.
  • Virocan Therapeutics Private Limited

心肌纖維症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

心肌纖維症:最近的開發平台趨勢

心肌纖維症:暫停中的計劃

心肌纖維症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8186IDB

Summary

Global Markets Direct's, 'Myocardial Fibrosis - Pipeline Review, H1 2016', provides an overview of the Myocardial Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myocardial Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Fibrosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Myocardial Fibrosis
  • The report reviews pipeline therapeutics for Myocardial Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Myocardial Fibrosis therapeutics and enlists all their major and minor projects
  • The report assesses Myocardial Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Myocardial Fibrosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Myocardial Fibrosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Myocardial Fibrosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Myocardial Fibrosis Overview
  • Therapeutics Development
    • Pipeline Products for Myocardial Fibrosis - Overview
    • Pipeline Products for Myocardial Fibrosis - Comparative Analysis
  • Myocardial Fibrosis - Therapeutics under Development by Companies
  • Myocardial Fibrosis - Therapeutics under Investigation by Universities/Institutes
  • Myocardial Fibrosis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Myocardial Fibrosis - Products under Development by Companies
  • Myocardial Fibrosis - Products under Investigation by Universities/Institutes
  • Myocardial Fibrosis - Companies Involved in Therapeutics Development
    • AstraZeneca Plc
    • Evotec AG
    • Galectin Therapeutics, Inc.
    • GTx, Inc.
    • Invivosciences, Inc.
    • MandalMed, Inc.
    • miRagen Therapeutics, Inc.
    • Regulus Therapeutics Inc.
    • Shire Plc
    • TRACON Pharmaceuticals, Inc.
  • Myocardial Fibrosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AZ-876 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs for Tissue Fibrosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GM-CT-01 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GRMD-02 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GTx-878 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MGN-4220 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Cardiovascular Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NM-922 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RG-012 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SHP-627 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Soluble Epoxide Hydrolase for Myocardial Fibrosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SP-20102 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TPI-2049 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TRC-105 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TRC-205 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Myocardial Fibrosis - Recent Pipeline Updates
  • Myocardial Fibrosis - Dormant Projects
  • Myocardial Fibrosis - Product Development Milestones
    • Featured News & Press Releases
      • Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Myocardial Fibrosis, H1 2016
  • Number of Products under Development for Myocardial Fibrosis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Myocardial Fibrosis - Pipeline by AstraZeneca Plc, H1 2016
  • Myocardial Fibrosis - Pipeline by Evotec AG, H1 2016
  • Myocardial Fibrosis - Pipeline by Galectin Therapeutics, Inc., H1 2016
  • Myocardial Fibrosis - Pipeline by GTx, Inc., H1 2016
  • Myocardial Fibrosis - Pipeline by Invivosciences, Inc., H1 2016
  • Myocardial Fibrosis - Pipeline by MandalMed, Inc., H1 2016
  • Myocardial Fibrosis - Pipeline by miRagen Therapeutics, Inc., H1 2016
  • Myocardial Fibrosis - Pipeline by Regulus Therapeutics Inc., H1 2016
  • Myocardial Fibrosis - Pipeline by Shire Plc, H1 2016
  • Myocardial Fibrosis - Pipeline by TRACON Pharmaceuticals, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Myocardial Fibrosis Therapeutics - Recent Pipeline Updates, H1 2016
  • Myocardial Fibrosis - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Myocardial Fibrosis, H1 2016
  • Number of Products under Development for Myocardial Fibrosis - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top